Weekly Analysts’ Ratings Updates for Charles River Laboratories International (CRL)

A number of firms have modified their ratings and price targets on shares of Charles River Laboratories International (NYSE: CRL) recently:

• 8/10/2026 – Charles River Laboratories International had its price target raised by TD Cowen from $235.00 to $300.00. They now have a “buy” rating on the stock.
• 8/10/2026 – Charles River Laboratories International was given a new $300.00 price target by Piper Sandler.
• 8/10/2026 – Charles River Laboratories International was given a new $264.00 price target by Mizuho.
• 8/7/2026 – Charles River Laboratories International had its price target raised by Morgan Stanley from $260.00 to $300.00. They now have an “overweight” rating on the stock.
• 8/6/2026 – Charles River Laboratories International was given a new $291.00 price target by Robert W. Baird.
• 8/6/2026 – Charles River Laboratories International had its price target raised by Royal Bank Of Canada from $215.00 to $282.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Charles River Laboratories International was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”. They now have a $310.00 price target on the stock, up from $180.00.
• 8/5/2026 – Charles River Laboratories International had its “overweight” rating reaffirmed by Barclays PLC. They now have a $300.00 price target on the stock.
• 8/5/2026 – Charles River Laboratories International had its “outperform” rating reaffirmed by Evercore Inc.
• 7/20/2026 – Charles River Laboratories International was downgraded by CLSA from “outperform” to “hold”. They now have a $219.00 price target on the stock.
• 7/13/2026 – Charles River Laboratories International had its price target raised by Mizuho from $192.00 to $230.00. They now have a “neutral” rating on the stock.
• 7/9/2026 – Charles River Laboratories International had its price target raised by Morgan Stanley from $220.00 to $260.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Charles River Laboratories International had its “buy” rating reaffirmed by Citigroup Inc..
• 7/1/2026 – Charles River Laboratories International was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/1/2026 – Charles River Laboratories International was given a new $250.00 price target by Sanford C. Bernstein.
• 7/1/2026 – Charles River Laboratories International was given a new $250.00 price target by BNP Paribas Exane.

Insider Buying and Selling

In related news, CAO Michael Gunnar Knell sold 6,645 shares of Charles River Laboratories International stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $260.38, for a total value of $1,730,225.10. Following the completion of the sale, the chief accounting officer owned 11,852 shares in the company, valued at approximately $3,086,023.76. This trade represents a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director James C. Foster sold 75,000 shares of the stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares in the company, valued at approximately $7,109,100. The trade was a 70.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 132,429 shares of company stock valued at $32,538,088 in the last ninety days. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.